OUR MISSION
Conduct translational genomics research that advances our knowledge and transforms the lives of patients with cancer and rare diseases.
We advance precision medicine by applying cutting-edge genomic technologies to cancer and rare diseases. In oncology, we study genomic and transcriptomic alterations in solid tumors to improve diagnosis and guide individualized therapy. In rare diseases, we focus on undiagnosed pediatric patients to overcome diagnostic dead ends, shorten the diagnostic odyssey, and uncover underlying genetic causes.
OUR KEY RESEARCH QUESTIONS include:
- Which genomic alterations drive the onset and progression of an individual disease?
- How does the disease reprogram cellular biology or epigenetics?
- What is the functional impact of novel genetic variants identified in patients, and how can these alterations be therapeutically targeted?
SPECIALIZED EXPERTISE AND TECHNOLOGY
Medical genomics techniques including next-generation and long-read sequencing
(including rapid trio setting), RNA sequencing, single-cell and spatial transcriptomics, and methylomeprofiling.
Functional genomics and genome modificitions (CRISPR/Cas9)
Processing of challenging biological material for genomic analyses (liquid biopsy, FFPE tissue samples)
ONDREJ SLABY
CONTACT INFORMATION
- Ondrej Slaby, Ph.D.
- Professor
- Senior Research Group Leader, Ondřej Slabý Research Group
- office: bldg. B06/209
Kamenice 753/5
625 00 Brno - phone: +420 549 49 1331e‑mail: oslaby@med.muni.cz
TRANSLATIONAL HUMAN GENOMICS
ABOUT RESEARCH
We advance precision medicine by applying cutting-edge genomic technologies to cancer and rare diseases. In oncology, we study genomic and transcriptomic alterations in solid tumors to improve diagnosis and guide individualized therapy. In rare diseases, we focus on undiagnosed pediatric patients to overcome diagnostic dead ends, shorten the diagnostic odyssey, and uncover underlying genetic causes.
Our key research questions include:
- Which genomic alterations drive the onset and progression of an individual disease?
- How does the disease reprogram cellular biology or epigenetics?
- What is the functional impact of novel genetic variants identified in patients, and how can these alterations be therapeutically targeted?
While our work often starts with broad, hypothesis-free analyses, it quickly generates specific biological questions. We address these using functional genomics to dissect mechanisms, validate candidate genes, and explore therapeutic vulnerabilities. We are developing a drug repurposing pipeline that leverages AI-based approaches, followed by experimental validation and clinical application in individual patients.
What sets our work apart is our uniquely close integration with the Center for Precision Medicineat University Hospital Brno — the only center of its kind in the Czech Republic.
We are a joint research group of the Faculty of Medicine (Department of Biology, CREATIC) and CEITEC at the Masaryk University.